BioArctic’s partner Eisai initiates BLA submission of data for lecanemab in China

Stockholm, December 23, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated submission of data for Biologics License Application (BLA) to the National Medical Products Administration (NMPA) of China for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody.

The release as fetched from its publisher. bioarctic.com ↗